Education
About Us
Working with TipRanks
Follow Us
DRKY - ETF AI Analysis
Top Page
VistaShares Target 15 DRUKMacro Distribution ETF (DRKY)
Rating:68Neutral
Price Target:―
Positive Factors
Strong Performers Among Top Holdings
Several major positions like Teva, TSMC, Woodward, Mercadolibre, and Amazon have shown positive performance, helping support the fund despite recent weakness.
Sector Diversification Across Growth Areas
The ETF spreads its investments across health care, consumer cyclical, technology, industrials, communication services, and financials, reducing reliance on any single industry.
Meaningful Fund Size
With tens of millions in assets under management, the fund is large enough to be established but still focused, which can help with trading and portfolio management.
Negative Factors
High Concentration in a Few Stocks
The top three holdings make up a large share of the portfolio, so poor performance in any of these companies can strongly affect the ETF.
Heavy Tilt Toward Health Care
Nearly half of the fund is in health care stocks, which increases exposure to sector-specific risks like regulation changes or drug trial setbacks.
High Fees and Recent Weak Performance
The ETF charges a relatively high expense ratio and has shown negative returns over the past month, three months, and year to date, which can weigh on investor outcomes.
DRKY vs. SPDR S&P 500 ETF (SPY)
AUM20.00M
RegionNorth America
Expense Ratio0.95%
Beta0.85
IssuerVistaShares
Inception DateOct 08, 2025
Dividend Yield5.14%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume12,341
30 Day Avg. Volume26,187
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
26.46Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering21
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
DRKY Summary
VistaShares Target 15 DRUKMacro Distribution ETF (DRKY) is an actively managed fund that follows a “total U.S. stock market” theme, guided by the investment ideas of Stanley Druckenmiller’s Duquesne Family Office rather than a fixed index. It mainly holds U.S. companies, with a big tilt toward health care, plus consumer and tech names. Well-known holdings include Amazon and Taiwan Semiconductor (TSMC). Investors might consider DRKY for broad stock exposure plus a focus on generating monthly income. A key risk is that it’s concentrated in a few sectors and stocks, so its price can move up and down more than the overall market.
How much will it cost me?The expense ratio for the VistaShares Target 15 DRUKMacro Distribution ETF (Ticker: DRKY) is 0.95%, meaning you’ll pay $9.50 per year for every $1,000 invested. This is higher than average because the fund is actively managed, using sophisticated strategies and insights from the Duquesne Family Office to maximize income and returns.
What would affect this ETF?The DRKY ETF, with its strong focus on U.S. equities and significant exposure to healthcare and technology sectors, could benefit from advancements in medical innovation and tech growth, especially if economic conditions remain favorable for these industries. However, its reliance on derivative strategies and concentration in specific sectors may pose risks during periods of market volatility or regulatory changes affecting healthcare and technology. Broader economic factors, such as interest rate hikes or a slowdown in consumer spending, could also impact the ETF's performance negatively.
DRKY Top 10 Holdings
DRKY is leaning heavily on health care, with Natera and Teva in the driver’s seat: Teva has been rising and helping the fund, while Natera’s recent slide is more of a speed bump. Insmed is also lagging, adding some drag to this biotech-heavy tilt. Outside health care, TSMC gives the portfolio a powerful semiconductor and AI engine, though its gains have cooled a bit. Woodward has been a quiet overachiever, while e-commerce names like Coupang and Amazon have shown mixed to weak momentum. Despite its U.S. focus, the fund’s top names add a global flavor through Taiwan and Latin America.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Natera | 17.32% | $3.49M | $29.81B | 28.64% | 73 Outperform | |
| Teva Pharmaceutical | 16.21% | $3.26M | $39.61B | 101.94% | 63 Neutral | |
| TSMC | 9.31% | $1.87M | $1.57T | 80.10% | 81 Outperform | |
| Insmed | 9.21% | $1.85M | $32.23B | 92.56% | 43 Neutral | |
| Woodward | 8.25% | $1.66M | $23.39B | 105.76% | 79 Outperform | |
| Mercadolibre | 4.82% | $970.37K | $101.85B | -5.40% | 77 Outperform | |
| Coupang | 3.56% | $716.93K | $32.97B | -26.58% | 60 Neutral | |
| Amazon | 3.09% | $623.18K | $2.20T | -8.08% | 71 Outperform | |
| DocuSign | 3.05% | $614.89K | $8.98B | -48.82% | 71 Outperform | |
| Figure Technology Solutions, Inc. Class A | 2.90% | $584.86K | $7.65B | ― | 68 Neutral |
DRKY Technical Analysis
Neutral
―
Price Trends
21.39
Negative
Market Momentum
-0.27
Positive
44.91
Neutral
64.07
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For DRKY, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 21.05, equal to the 50-day MA of 21.39, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of -0.27 indicates Positive momentum. The RSI at 44.91 is Neutral, neither overbought nor oversold. The STOCH value of 64.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DRKY.
DRKY Peer Comparison
Comparison Results
Performance Comparison
DRKY
VistaShares Target 15 DRUKMacro Distribution ETF
20.77
1.55
8.06%
BAMD
Brookstone Dividend Stock ETF
―
―
―
SOVF
Sovereign's Capital Flourish Fund
―
―
―
STNC
Stance Equity ESG Large Cap Core ETF
―
―
―
RFDA
RiverFront Dynamic US Dividend Advantage ETF
―
―
―
VAMO
Cambria Value & Momentum ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents